Literature DB >> 2839606

A recombinant vaccinia virus expressing herpes simplex virus type 1 glycoprotein B induces cytotoxic T lymphocytes in mice.

E McLaughlin-Taylor1, D E Willey, E M Cantin, R Eberle, B Moss, H Openshaw.   

Abstract

Spleen cells from BALB/c (H-2d) mice vaccinated with vgB11, a recombinant vaccinia virus which expresses glycoprotein B (gB) of herpes simplex virus type 1 (HSV-1), lysed EMT6 (H-2d) target cells infected with vgB11 or with HSV-1 but did not lyse uninfected EMT6 cells or infected L-929 (H-2k) target cells. Unlabelled target cell competition of lysis showed that only syngeneic cells infected with vgB11 or HSV-1 inhibited lysis of radiolabelled HSV-1-infected targets. These results demonstrate that vgB11 induces H-2-restricted anti-HSV-1 cytotoxic T lymphocytes and that gB is the target antigen.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839606     DOI: 10.1099/0022-1317-69-7-1731

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  15 in total

1.  The simian herpesvirus SA8 homologue of the herpes simplex virus gB gene: mapping, sequencing, and comparison to the HSV gB.

Authors:  R Eberle; D Black
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

2.  Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides.

Authors:  T Hanke; F L Graham; K L Rosenthal; D C Johnson
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

3.  Characterization of diverse primary herpes simplex virus type 1 gB-specific cytotoxic T-cell response showing a preferential V beta bias.

Authors:  S C Cose; J M Kelly; F R Carbone
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

4.  The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant.

Authors:  M E Wallace; R Keating; W R Heath; F R Carbone
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

5.  Deletion of the carboxy-terminus of herpes simplex virus type 1 (HSV-1) glycoprotein B does not affect oligomerization, heparin-binding activity, or its ability to protect against HSV challenge.

Authors:  X H Lin; M A Ali; H Openshaw; E M Cantin
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

6.  Herpes simplex virus type 1-specific cytotoxic T-lymphocyte arming occurs within lymph nodes draining the site of cutaneous infection.

Authors:  C M Jones; S C Cose; R M Coles; A C Winterhalter; A G Brooks; W R Heath; F R Carbone
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection.

Authors:  L H Nguyen; D M Knipe; R W Finberg
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

8.  Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection.

Authors:  D McMahon-Pratt; D Rodriguez; J R Rodriguez; Y Zhang; K Manson; C Bergman; L Rivas; J F Rodriguez; K L Lohman; N H Ruddle
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

9.  Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.

Authors:  H E Farrell; C S McLean; C Harley; S Efstathiou; S Inglis; A C Minson
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1.

Authors:  M A Brehm; R H Bonneau; D M Knipe; S S Tevethia
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.